Raf kinases are a family of three serine/threonine-specific protein kinases that are related to retroviral oncogenes.Rapidly Accelerated Fibrosarcoma is referred to as RAF. The RAS-RAF-MEK-ERK signal transduction cascade, also known as the mitogen-activated protein kinase (MAPK) cascade, involves Raf kinases. Interaction with RAS-GTPases is necessary for RAF kinase activation. A-RAF, B-RAF, and C-RAF (Raf-1) are the three members of the RAF kinase family. The B-Raf protein is involved in transmitting signals within cells that control cell growth.It was demonstrated that it was flawed (mutated) in a few human cancers. The RAF1 gene in humans encodes the enzyme C-RAF, also known as Raf-1. The c-Raf protein is a MAP kinase kinase (MAP3K) that works after the Ras subfamily of membrane-associated GTPases. It is a component of the ERK1/2 pathway. C-Raf is a member of the TKL (Tyrosine-kinase-like) group of protein kinases and belongs to the Raf kinase family of serine/threonine-specific protein kinases.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V13500 | Exarafenib | 2639957-39-2 | Exarafenib (RAF/KIN_2787) is an orally bioactive pan-RAF inhibitor. |
|
V1005 | GDC-0879 | 905281-76-7 | GDC-0879 (AR-00341677;GDC-0879; AR00341677) is a novel, potent, highly selective, and orally bioavailable B-Raf kinase inhibitor with potential antitumor activity. |
|
V51457 | GNE-9815 | 2729996-45-4 | Type II pan-RAF inhibitor |
|
V1011 | GW5074 | 220904-83-6 | GW5074 (GW-5074; GW 5074) is a novel, potent and selective c-Raf inhibitor with potential neuroprotective activity. |
|
V74140 | ISIS 5132 (CGP 69846A; ISIS 9271) | 177075-18-2 | ISIS 5132 is an oligonucleotide that specifically downregulates c-raf expression. |
|
|
V80402 | ISIS 5132 sodium (CGP 69846A sodium; ISIS 9271 sodium) | ISIS 5132sodium is an oligonucleotide that specifically downregulates c-raf expression. | |
|
V23607 | L-779450 | 303727-31-3 | L-779450 is a potent, selective and ATP-competitive Raf kinase inhibitor (IC50 = 10 nM). |
|
V4222 | LUT-014 | 2274819-46-2 | LUT014 is a novel, potent and topical B-Raf Inhibitor which is a proprietary, first-in-class, small molecule allowing administration of EGFR (Epidermal Growth Factor Receptor) Inhibitors to patients without interruptions caused by typical cutaneous side effects. |
|
V1015 | LY3009120 (DP-4978) | 1454682-72-4 | LY03009120 (DP4978;LY-3009120;LY-03009120;DP-4978) is a novel and potent pan-Raf inhibitor with potential anticancer activity. |
|
V2669 | MLN2480 (TAK-580) | 1096708-71-2 | MLN2480 (BIIB-024;BSK1369; DAY-101;TAK-580;AMG-2112819)is an orally bioactive, potent and selective pan-Raf kinase inhibitor with potential anticancer activity. |
|
V5307 | Naporafenib (LXH-254) | 1800398-38-2 | Naporafenib (LXH254;LXH-254),extracted from patent WO2018051306A1, compound A, is a novel, potent and orally bioavailable C-RAF inhibitor with anticancer activity. |
|
V1007 | NVP-BHG712 (BHG712) | 940310-85-0 | NVP-BHG712 (NVP BHG-712;NVP BHG712;BHG-712) is a selective and orally bioavailable EphB4 inhibitor with potential anticancer activity. |
|
V74137 | Pan-RAF kinase inhibitor 1 | 2648838-76-8 | Pan-RAF kinase inhibitor 1 (compound 16B) is a potent Pan-RAF kinase inhibitor. |
|
V5142 | Plixorafenib (PLX8394) | 1393466-87-9 | PLX8394 (PLX-8394) is a novel, potent,orally bioavailable and selectiveinhibitor of the serine/threonine-protein kinase B-raf (BRaf) with anticancer activity. |
|
V1002 | PLX-4720 | 918505-84-7 | PLX4720 (PLX-4720; PLX 4720), a 7-azaindole/pyrrolopyridine-based vemurafenib derivative discovered by a structure-guided discovery approach, is a novel, potent and selective inhibitor of B-RafV600E mutant with potential antitumor activity. |
|
V74149 | PLX-4720-d7 | 1304096-50-1 | PLX-4720-d7 is the deuterium labelled form of PLX-4720. |
|
V2666 | PLX7904 | 1393465-84-3 | PLX7904 (also known as PLX-7904; PB04; PB-04) is a novel potent and selective paradox-breaker B-Raf inhibitor with anticancer activity. |
|
V74135 | PLX7922 | 1638772-61-8 | PLX7922 is a RAF inhibitor that binds to BRAFV600E. |
|
V74138 | R18 (PHCVPRDLSWLDLEANMCLP) | 211364-78-2 | R18 is a bioactive peptide antagonist of 14-3-3 with a Kd of 70-90 nM. |
|
V76571 | R18 TFA (PHCVPRDLSWLDLEANMCLP TFA) | R18 TFA is a bioactive peptide antagonist of 14-3-3 with a Kd of 70-90 nM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
